Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback